Vernalis Research, a subsidiary of HitGen Inc., is a leading company based in Berwyn, PA, specializing in fragment and structure-based drug discovery. Their team of experienced scientists at fully-equipped research laboratories in Cambridge, UK, integrates cutting-edge technologies to develop cell-active lead compounds and development candidates targeting oncology, neurodegeneration, anti-infectives, and inflammation.
With a focus on collaboration, Vernalis Research balances an internal portfolio of drug discovery projects with research partnerships with pharmaceutical, biotechnology companies, and academic institutions. Their shared-risk approach ensures high engagement from scientists and successful outcomes, with recent collaborations including Servier, Lundbeck, and Genentech.
Generated from the website